InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by ARMEN GARO H, Chairman & CEO. Insider active across 1 companies, notably AGENUS INC. Cumulatively, 14 reports have been published. The latest transaction was disclosed on 2 February 2022 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations14 total
€527,674237,011 shares@ €2.22640.35% mcap56.9% of flow
Common Stock
SEC:0000899243-22-004867·
€527,674237,011 shares@ €2.22640.35% mcap28.4% of flow
Common Stock
SEC:0000899243-22-004867:0·
€339,011119,178 shares@ €2.84460.23% mcap36.5% of flow
Common Stock
SEC:0000899243-21-035844·
€339,011119,178 shares@ €2.84460.23% mcap18.3% of flow
Common Stock
SEC:0000899243-21-035844:0·
€12,4832,679 shares@ €4.65970.0084% mcap1.3% of flow
Common Stock
SEC:0000899243-21-027363·
€12,4832,679 shares@ €4.65970.0084% mcap0.7% of flow
Common Stock
SEC:0000899243-21-027363:0·
€12,4162,812 shares@ €4.41520.0083% mcap1.3% of flow
Common Stock
SEC:0000899243-21-025019·
€12,4162,812 shares@ €4.41520.0083% mcap0.7% of flow
Common Stock
SEC:0000899243-21-025019:0·
€12,1903,670 shares@ €3.32150.0082% mcap1.3% of flow
Common Stock
SEC:0000899243-21-022383·
€12,1903,670 shares@ €3.32150.0082% mcap0.7% of flow
Common Stock
SEC:0000899243-21-022383:0·
€12,0983,530 shares@ €3.42730.0081% mcap1.3% of flow
Common Stock
SEC:0000899243-21-020399·
€12,0983,530 shares@ €3.42730.0081% mcap0.7% of flow
Common Stock
SEC:0000899243-21-020399:0·
€12,2534,817 shares@ €2.54380.0082% mcap1.3% of flow
Common Stock
SEC:0000899243-21-018729·
€12,2534,817 shares@ €2.54380.0082% mcap0.7% of flow
Common Stock
SEC:0000899243-21-018729:0·
14 of 14 declarations
About ARMEN GARO H
Garo H. Armen is the Chairman and CEO of Agenus Inc. He leads the company and oversees its strategic operations. With extensive experience in the biopharmaceutical sector, Garo is responsible for the strategic direction and growth of Agenus. His leadership is essential for the development of new therapies and for innovation within the company.
